Inventor · disambiguated record
Anne De Groot
Also filed as: DE GROOT ANNE · DE GROOT ANNE S · DE GROOT ANNE SEARLS
18 granted patents·26 pending applications·98 citations·filing 2002–2024
94Inventor score
Files withEPIVAX INC35EPIVAX ONCOLOGY INC2EPIVAX THERAPEUTICS INC2DBV TECH1MASSACHUSETTS GEN HOSPITAL1
Top patents by PatentIndex Score
44 records- 0198US7884184B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2008·Granted Feb 8, 2011·72 cites·13 claims
- 0290US10980867B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2019·Granted Apr 20, 2021·3 cites·10 claims
- 0390US10925942B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2019·Granted Feb 23, 2021·3 cites·10 claims
- 0489US10925939B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Feb 23, 2021·3 cites·10 claims
- 0589US10925941B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Feb 23, 2021·3 cites·10 claims
- 0689US10925940B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Feb 23, 2021·3 cites·10 claims
- 0789US10751397B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Aug 25, 2020·3 cites·10 claims
- 0888US10213496B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2015·Granted Feb 26, 2019·3 cites·10 claims
- 0983US11045528B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Jun 29, 2021·1 cites·19 claims
- 1083US11045530B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Jun 29, 2021·1 cites·19 claims
- 1183US11045532B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Jun 29, 2021·1 cites·19 claims
- 1283US11045529B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Jun 29, 2021·1 cites·19 claims
- 1383US11045531B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Jun 29, 2021·1 cites·19 claims
- 1483US2022211827A1Regulatory t cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2022·Application pending·0 cites
- 1580US12016909B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2021·Granted Jun 25, 2024·0 cites·19 claims
- 1680US11844826B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2021·Granted Dec 19, 2023·0 cites·10 claims
- 1775US2024316101A1Regulatory t cell epitopesEPIVAX INC·Filed 2024·Application pending·0 cites
- 1874US2019351036A1Regulatory t cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2019·Application pending·0 cites
- 1971US11911414B2Regulatory T cell epitopesEPIVAX INC·Filed 2021·Granted Feb 27, 2024·0 cites·9 claims
- 2070US2023279072A1Regulatory t cell epitopesEPIVAX INC·Filed 2022·Application pending·0 cites
- 2169US2023190915A1T cell epitopes and related compositions useful in the prevention, diagnosis, and treatment of covid-19EPIVAX INC·Filed 2021·Application pending·0 cites
- 2267US2023242591A1Regulatory t cell epitopes and detolerized sars-cov-2 antigensEPIVAX INC·Filed 2021·Application pending·0 cites
- 2367US2022378889A1Neo-epitope vaccines and methods of treating cancerEPIVAX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2467US2023151061A1T cell epitope clusters and related compositions useful in the prevention, diagnosis, and treatment of covid-19EPIVAX INC·Filed 2021·Application pending·0 cites
- 2565US2022362365A1Improved compositions and methods for shared neo-epitope vaccinesEPIVAX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2662US2021300985A1Regulatory t cell epitopesEPIVAX INC·Filed 2021·Application pending·0 cites
- 2761US2011182921A1Regulatory t cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2010·Application pending·0 cites
- 2859US2021154280A1Neo-epitope vaccines and methods of treating cancerEPIVAX ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 2959US2021145951A1Compositions and methods for shared neo-epitope vaccinesEPIVAX ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 3058US2018161419A1Methods for improving the efficacy of vaccine antigensEPIVAX INC·Filed 2017·Application pending·0 cites
- 3157US2024173377A1Retro - inverso regulatory t cell epitopesEPIVAX INC·Filed 2021·Application pending·0 cites
- 3257US2023321237A1Regulatory t cell epitopesEPIVAX INC·Filed 2021·Application pending·0 cites
- 3356US2024342273A1Immunotherapeutic method for increasing cashew tolerance in a subjectDBV TECH·Filed 2021·Application pending·0 cites
- 3456US2019105386A1Methods for improving the efficacy of vaccine antigensEPIVAX INC·Filed 2018·Application pending·0 cites
- 3555US2023158165A1Tregitope constructs useful in the prevention and treatment of type 1 diabetesEPIVAX INC·Filed 2021·Application pending·0 cites
- 3654US10286063B2Modified H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequenceEPIVAX INC·Filed 2016·Granted May 14, 2019·0 cites·11 claims
- 3753US2023192777A1Epitopic vaccine for african swine fever virusEPIVAX INC·Filed 2020·Application pending·0 cites
- 3850US2022125900A1Neoantigens in cancerRICHARD GUILHEM·Filed 2021·Application pending·0 cites
- 3949US2023127506A1Modified interferon-alpha-2 having reduced immunogenicityEPIVAX INC·Filed 2020·Application pending·0 cites
- 4049US2022023412A1Compositions Useful in Both Homologous And Heterologous Vaccine RegimensUNIV OF RHODE ISLAND BOARD OF TRUSTEES·Filed 2021·Application pending·0 cites
- 4149US2018161420A1Modified H7 Hemagglutinin Glycoprotein of the Influenza A/Shanghai/2/2013 H7 SequenceEPIVAX INC·Filed 2018·Application pending·0 cites
- 4247US2005048073A1Methods of determining west nile virus epitopes and method of using the sameFiled 2002·Application pending·0 cites
- 4345US11690902B2Coxiella burnetii epitopes for T cell-targeted Q fever vaccinesMASSACHUSETTS GEN HOSPITAL·Filed 2019·Granted Jul 4, 2023·0 cites·13 claims
- 4437US2018179256A1Modified H7 Hemagglutinin Glycoprotein of the Influenza A/Shanghai/2/2013 H7 SequenceEPIVAX INC·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →